Ticker name:NTRANatera, Inc.

Country: US-Sector: Healthcare, Industry: Medical - Diagnostics & Research

terraforming in: 2025

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Market Cap 38B

Last close 262.63$

Key metrics

Largest 20 companies In Medical - Diagnostics & Research

# PositionTickerCompany NameMarket CapLast PriceAction
1TMOTHERMO FISHER SCIENTIFIC INC.196B526.23$
2DHRDANAHER CORP /DE/142B201.11$
3IDXXIDEXX LABORATORIES INC /DE44B563.81$
4NTRANatera, Inc.38B262.63$
5AAGILENT TECHNOLOGIES, INC.37B130.26$
6WATWATERS CORP /DE/35B357.54$
7IQVIQVIA HOLDINGS INC.34B203.9$
8ILMNILLUMINA, INC.28B184.68$
9MTDMETTLER TOLEDO INTERNATIONAL INC/26B1273.77$
10LHLABCORP HOLDINGS INC.23B281.48$
11DGXQUEST DIAGNOSTICS INC23B207.66$
12GHGuardant Health, Inc.20B148.07$
13MEDPMedpace Holdings, Inc.15B527.93$
14ICLRICON PLC13B166.18$
15RVTYREVVITY, INC.12B106.44$
16CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.11B219.7$
17QGENQIAGEN N.V.8.3B40.48$
18BLLNBillionToOne, Inc.5.8B125.14$
19TWSTTwist Bioscience Corp5.4B87.45$
20SHCSotera Health Co5B17.42$